Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

StressGen prepares to evaluate Oncocine in clinical trials

Dec. 9, 1997

Seragen submits BLA for CTCL biological product

Dec. 9, 1997

IL-12 for treatment of malignant tumors

Dec. 8, 1997

OncoVax-P clinical data reported at scientific meeting

Dec. 5, 1997

Maxim reports promising data from AML trial with Maxamine

Dec. 4, 1997

Virulizin interim phase I/II results in advanced pancreatic cancer

Dec. 2, 1997

Rituximab launched in Switzerland

Nov. 28, 1997

First anticancer monoclonal antibody approved by FDA

Nov. 27, 1997

Results from Leuvectin trial in kidney cancer patients reported

Nov. 26, 1997

Phase I trial of multiple-dose IDEC-C2B8 in NHL

Nov. 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...